Table 1 Comparison of clinical characteristics between Malaysian renal transplant recipients who developed NODAT and those without NODAT at 1-year post- transplant
|  | All patients (n = 168) N (%) or mean ± SD | NODAT (n = 29) N (%) or mean ± SD | NON-NODAT (n = 139) N (%) or mean ± SD | p |
|---|---|---|---|---|
Gender | Â | Â | Â | 0.70 |
 - Male | 98 (58) | 16 (6) | 82 (84) |  |
 - Female | 70 (42) | 13 (19) | 57 (81) |  |
Age at transplant | 34.8 (12.1) | 39.3 ± 13.4 | 33.9 ± 11.8 | 0.03 |
Ethnicities | Â | Â | Â | 0.84 |
 - Malay | 34 (20) | 5 (15) | 29 (85) |  |
 - Chinese | 115 (69) | 20 (17) | 95 (83) |  |
 - Indian | 19 (11) | 4 (11) | 15 (79) |  |
Primary kidney disease | Â | Â | Â | 0.20 |
 - Glomerulonephritis | 51 (30) | 9 (18) | 42 (82) |  |
 - Hypertension | 19 (11) | 6 (32) | 13 (68) |  |
 - Others | 98 (59) | 14 (14) | 84 (86) |  |
Type of donor | Â | Â | Â | 0.76 |
 - Living related | 71 (45) | 11 (15) | 60 (85) |  |
 - Living non-related | 20 (42) | 3 (15) | 17 (85) |  |
 - Cadaveric | 77 (12) | 15 (20) | 62 (80) |  |
Place of transplant | Â | Â | Â | 0.05 |
 - Local | 114 (67) | 15 (13) | 98 (87) |  |
 - Overseas | 54 (32) | 14 (26) | 40 (74) |  |
Types of calcineurin inhibitors | Â | Â | Â | 0.66 |
 - Cyclosporine | 90 (54) | 15 (17) | 75 (83) |  |
 - Tacrolimus | 67 (40) | 11 (16) | 56 (84) |  |
 - Both | 11 (6) | 3 (27) | 8 (73) |  |
Duration of dialysis (month) | 33.0 (40.5) | 23.1 ± 23.5 | 35.5 ± 43.3 | 0.09 |
BMI (kg/m2) | 21.3 (4.6) | 21.9 ± 4.6 | 21.1 ± 4.4 | 0.35 |
Levels of creatinine (μmol/L) | 127 (122.6) | 112.24 ± 34.2 | 130.11 ± 99.1 | 0.68 |
Fasting blood glucose (μmol/L) | 5.5 (1.4) | 6.5 ± 1.8 | 5.2 ± 0.7 | < 0.0001 |
Average daily dose of cyclosporine (mg/kg) | 295.4 (116.5) | 328.8 ± 125.8 | 280.6 ± 92.3 | 0.15 |
Average daily dose of tacrolimus (mg/day) | 7.5 (3.4) | 7.5 ± 3.1 | 7.8 ± 2.4 | 0.55 |
Average daily dose of prednisolone (mg/day) | 15.8 (4.4) | 16.2 ± 2.6 | 15.8 ± 2.6 | 0.45 |